Stanford V (usually spoken as Stanford Five), is a chemotherapy regimen (with accompanying radiation therapy) intended as a first-line treatment for Hodgkin lymphoma. The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens such as ABVD. The chemical agents used are: A mustard derivative such as cyclophosphamide, chlormethine or ifosfamide Doxorubicin, an anti-tumor antibiotic Vinblastine, an alkaloid cell toxin Vincristine, another alkaloid cell toxin Bleomycin, another anti-tumor antibiotic Etoposide, a DNA toxin Prednisone, a corticosteroid
Drug Regimen The chemotherapy part of Stanford V treatment can last anywhere from 8 to 12 weeks, depending on the staging of the disease. In many cases, this is followed by radiation therapy for anywhere from 2 to 6 weeks to the affected areas of the body.
Stanford V is a more rigorously administered form of chemotherapy, with treatments roughly twice as fast as those of other Hodgkin lymphoma treatments. However, in a randomized controlled study, Stanford V was inferior to ABVD. This study has been criticize for not adhering to the proper Stanford V protocol. Specifically, the radiation therapy component following chemotherapy was not properly administered in the Italian study. A retrospective study from the Memorial Sloan-Kettering Cancer Center displayed results similar to the Stanford Cancer Center's own experience. The study concluded that, "Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL."
Drug Dose Mode Days Doxorubicin 25 mg/m2 IV Days 1 and 15 Vinblastine 6 mg/m2 IV Days 1 and 15 Chlormethine 6 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 (max 2 mg) IV Days 8 and 22 Bleomycin 5 units/m2 IV Days 8 and 22 Etoposide 60 mg/m2 IV Days 15, 16 Prednisone 40 mg/m2 PO Q2D
References
External links Lymphoma Information Network
Includes table for schedule